Endocrine-Related Cancer

Suggested recommendation for biochemical evaluation and monitoring of pituitary dysfunction in patients treated with immunotherapy. ^$When using anti-CTLA4, anti-PD-(L)1 baseline and if symptoms persist on *2 years of follow-up, **high-dose steroids in patients with critical illness, in patients with severe hyponatremia, severe headache, visual abnormalities from pituitary enlargement and low-dose steroids (e.g. hydrocortisone 20–30 mg/day) with mild symptoms such as fatigue, mild headache. ^&Should be considered to selected premenopausal women. ACTH, adrenocorticotrophic hormone; FSH, follicle-stimulating hormone; fT₄, free thyroxine; LH, luteinizing hormone; mo, months; T₃, triiodothyronine; TSH, thyroid-stimulating hormone; WNL, within normal range.